Regional Support to Address the Outbreak of Coronavirus Disease 2019 and Potential Outbreaks of Other Communicable Diseases: Vaccine Regulation Firm
February 2023 – Ongoing
Health products regulation enables access to safe, efficacious and quality health products through a range of scientific and regulatory activities deployed across the entire product life cycle, including manufacturing and surveillance. The COVID-19 pandemic has exposed gaps in vaccine regulation at the national level, in particular low-resourced developing member countries (DMCs).
To address this, the Centre of Regulatory Excellence is collaborating with the Health Sector Group of the Asian Development Bank (ADB) to strengthen the regulatory resilience for public health emergencies. This is a part of ADB’s Support to Enhance COVID-19 Vaccine Access by Developing Member Countries (APVAX) programme.
The current project aims to inform the Health Sector Group of the Asian Development Bank on the regulatory landscape in Asia and the Pacific, focusing on regulatory systems strengthening as well as regulatory factors for vaccine manufacturing in Bangladesh.
These priority areas will lay the foundations to build functional national regulatory systems and strengthen regulatory resilience for public health emergencies in DMCs, which are pivotal in encouraging equitable access to innovative health products, attracting investments in manufacturing and enhancing public health surveillance systems in this region.
For more information about the project you can contact firstname.lastname@example.org
- Past ADB-CoRE Project